Related Experiment Video
Updated: Apr 29, 2026
12:24
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
7.2K
Evaluated outcomes in patients with Chronic Hepatitis C
Sara Ashtari1, Mohsen Vahedi2, Mohammad Amin Pourhoseingholi1
1Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran.
Gastroenterology and Hepatology From Bed to Bench
|May 17, 2014
Summary
Pegylated interferon plus ribavirin (PEG-RBV) significantly improves sustained virological response (SVR) rates for chronic hepatitis C compared to interferon plus ribavirin (INF-RBV). Genotype 3a also shows a higher chance of achieving SVR with PEG-RBV treatment.
Area of Science:
- Hepatology
- Virology
- Clinical Medicine
Background:
- Hepatitis C virus (HCV) infection remains a global health concern.
- Pegylated interferon plus ribavirin (PEG-RBV) is a standard HCV treatment, but interferon plus ribavirin (INF-RBV) is still used in some developing countries due to cost.
- Real-world outcomes of these treatments in specific populations are crucial for treatment guidelines.
Purpose of the Study:
- To compare the real-world effectiveness of INF-RBV and PEG-RBV in treating chronic hepatitis C patients.
- To evaluate sustained virological response (SVR) rates and influencing factors.
Main Methods:
- A cross-sectional study involving 77 treatment-naïve chronic hepatitis C patients in Tehran.
- Patients received either INF-RBV or PEG-RBV combination therapy according to standard protocols.
- SVR rates were assessed at the end of treatment.
Main Results:
- The SVR rate was 37.2% for INF-RBV and 67.6% for PEG-RBV.
- Patients receiving PEG-RBV had significantly higher SVR rates compared to those on INF-RBV.
- Hepatitis C genotype 3a was associated with a higher likelihood of achieving SVR when treated with PEG-RBV.
Conclusions:
- PEG-RBV demonstrates superior efficacy in achieving SVR for chronic hepatitis C compared to INF-RBV.
- Hepatitis C genotype 3a is a favorable predictor for SVR achievement with PEG-RBV therapy.
Related Concept Videos
01:25Hepatitis
81
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
81
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
01:28Viral Hepatitis I: Introduction
25
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
25
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
01:24Cirrhosis II: Pathophysiology
41
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
41
01:23Cirrhosis I: Introduction
28
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
28